See today's BioWorld
To read the full story, subscribe or sign in.

'HAE' now, don't dream: Kalvista game hardly over, bid enters crowded house

July 18, 2019
By Randy Osborne
Kalvista Pharmaceuticals Inc. made big news in October 2017 by way of its handsome deal with Merck & Co. Inc. to advance KVD-001, an intravitreal injection candidate to treat diabetic macular edema (DME).
BioWorld Deals and M&A License